InvestorsHub Logo
Followers 33
Posts 2844
Boards Moderated 1
Alias Born 10/24/2015

Re: None

Wednesday, 03/23/2022 10:27:39 PM

Wednesday, March 23, 2022 10:27:39 PM

Post# of 550
The IDMC has recommended that the PhIII trial in ovarian should continue following an interim analysis. The analysis showed that an increase in sample size is not necessary and the committee recommended that the trial continue to a final analysis.

The primary endpoint of INNOVATE-3, which is examining TTFs in combination with paclitaxel for platinum-resistant ovarian, is OS. Secondary endpoints include PFS, ORR, and severity and frequency of AEs.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVCR News